Literature DB >> 10924916

Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide.

R A Ross1, H C Brockie, R G Pertwee.   

Abstract

We have investigated the inhibition of lipopolysaccharide stimulated nitric oxide production in RAW264.7 macrophages by the cannabinoids and the putative cannabinoid CB(2)-like receptor ligand, palmitoylethanolamide. (R)-(+)-[2, 3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate ((+)-WIN55212) and, to a lesser extent (-)-cis-3-[2-hydroxy-4-(1, 1-dimethylheptyl)phenyl]-trans-4-(3-hydroxy-propyl)cyclohexan++ +-1-ol (CP55940), significantly inhibited lipopolysaccharide stimulated nitric oxide production. The level of inhibition was found to be dependent on the concentration of lipopolysaccharide used to induce nitric oxide production. Palmitoylethanolamide significantly inhibited nitric oxide production induced by lipopolysaccharide. The inhibition of nitric oxide production by (+)-WIN55212 but not palmitoylethanolamide was significantly attenuated in the presence of the cannabinoid CB(2) receptor antagonist, N-[(1S)-endo-1,3, 3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazo le- 3-carboxamide (SR144528). (+)-WIN55212 produced a pertussis toxin-sensitive parallel rightward shift in the log concentration-response curve for lipopolysaccharide, causing a fivefold increase in the EC(50) value for lipopolysaccharide with no change in the E(max) value. (-)-WIN55212 had no effect on the log concentration-response curve for lipopolysaccharide. Palmitoylethanolamide did not produce a rightward shift in the lipopolysaccharide concentration-response curve. However, it did produce a pertussis toxin-insensitive reduction in the E(max) value. The results suggest that the inhibition of lipopolysaccharide mediated nitric oxide release by (+)-WIN55212 in murine macrophages is mediated by cannabinoid CB(2) receptors. In contrast, the inhibition by palmitoylethanolamide does not appear to be mediated by cannabinoid receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924916     DOI: 10.1016/s0014-2999(00)00437-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  37 in total

1.  Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Carolina Simioni; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Evaluation of fatty acid amides in the carrageenan-induced paw edema model.

Authors:  Laura E Wise; Roberta Cannavacciulo; Benjamin F Cravatt; Billy F Martin; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2007-06-22       Impact factor: 5.250

3.  Peripheral cannabinoid receptor, CB2, regulates bone mass.

Authors:  Orr Ofek; Meliha Karsak; Nathalie Leclerc; Meirav Fogel; Baruch Frenkel; Karen Wright; Joseph Tam; Malka Attar-Namdar; Vardit Kram; Esther Shohami; Raphael Mechoulam; Andreas Zimmer; Itai Bab
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-09       Impact factor: 11.205

Review 4.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

Review 5.  Endocannabinoid signalling in innate and adaptive immunity.

Authors:  Valerio Chiurchiù; Luca Battistini; Mauro Maccarrone
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

6.  Cannabinoid Receptor 2 Modulates Susceptibility to Experimental Cerebral Malaria through a CCL17-dependent Mechanism.

Authors:  Judith Alferink; Sabine Specht; Hannah Arends; Beatrix Schumak; Kim Schmidt; Christina Ruland; Ramona Lundt; Andrea Kemter; Andrea Dlugos; Janina M Kuepper; Karola Poppensieker; Matthias Findeiss; Önder Albayram; David-M Otte; Janine Marazzi; Jürg Gertsch; Irmgard Förster; Wolfgang Maier; Stefanie Scheu; Achim Hoerauf; Andreas Zimmer
Journal:  J Biol Chem       Date:  2016-07-29       Impact factor: 5.157

7.  Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice.

Authors:  R Capasso; A A Izzo; F Fezza; A Pinto; F Capasso; N Mascolo; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

8.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

9.  The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.

Authors:  B Romano; F Borrelli; I Fasolino; R Capasso; F Piscitelli; Mg Cascio; Rg Pertwee; D Coppola; L Vassallo; P Orlando; V Di Marzo; Aa Izzo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  The neuroprotective properties of palmitoylethanolamine against oxidative stress in a neuronal cell line.

Authors:  R Scott Duncan; Kent D Chapman; Peter Koulen
Journal:  Mol Neurodegener       Date:  2009-12-10       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.